Maxwell R Lloyd,Mark D Pegram,Seth A Wander
Maxwell R Lloyd
HER2-directed tyrosine kinase inhibitor combinations with trastuzumab represent an emerging strategy for hormone receptor-negative or -positive metastatic breast cancer with activating HER2 mutations. Correlative genomics reveal on-target a...
Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer [0.03%]
MTAP缺失型晚期非小细胞肺癌患者的临床特征及系统治疗预后分析
Julian Huang,Mihaela Aldea,Kathryn W Miller et al.
Julian Huang et al.
Purpose: Methylthioadenosine phosphorylase (MTAP) is deleted in 13% of NSCLC, and MTAP two-copy deleted (MTAPdel) cancer cells are vulnerable to protein arginine methyltransferase 5 inhibitors being examined in trials. Ou...
Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer [0.03%]
用于监测复发性膀胱癌的多重尿液生物标志物检测的临床验证
Yair Lotan,Michael Luu,Menghan Liu et al.
Yair Lotan et al.
Background: More than 50% of patients with non-muscle invasive bladder cancer (NMIBC) experience recurrence, requiring lifelong surveillance with repeated cystoscopy. Given the invasive nature and cost of cystoscopy, accu...
Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma [0.03%]
表观遗传液体活检可对高危神经母细胞瘤进行通用的分子监测
Nurit Gal-Mark,Assaf Grunwald,Valid Gahramanov et al.
Nurit Gal-Mark et al.
Purpose: Liquid biopsy monitoring in pediatric solid tumors is limited by low mutational burden and lack of trackable genomic drivers. We sought to develop a mutation-agnostic, methylation-based liquid biopsy framework en...
Mina Nikanjam,Judith Pérez-Granado,Mark W Gramling et al.
Mina Nikanjam et al.
Claudin 18.2 (CLDN18.2) is exclusively expressed on gastric mucosal cell tight junctions with minimal expression in other healthy adult tissues. Prior studies assessed expression by immunohistochemistry, mainly membrane staining. The FDA CL...
High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer [0.03%]
高灵敏度ctDNA分析发现NGS遗漏的胰腺癌信号
Krishay Sridalla,Jasmine K Machhi,Dominic J Vitello et al.
Krishay Sridalla et al.
Purpose: Pancreatic ductal adenocarcinoma (PDAC) carries high mortality despite multimodal therapy, and improved biomarkers are needed to guide perioperative care. This study evaluated the prognostic significance of KRAS-...
Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG [0.03%]
儿童脑肿瘤联盟关于CD40激动剂sotigalimab治疗复发性中枢神经系统肿瘤患儿和新诊断的弥漫内生性桥脑胶质瘤年轻患者的1期研究
Holly B Lindsay,Catherine A Billups,Mehmet Kocak et al.
Holly B Lindsay et al.
Purpose: The PBTC-051 study is the first pediatric evaluation of a CD40 agonist and assessed the safety, pharmacokinetics, and preliminary efficacy of sotigalimab in children and young adults with recurrent or progressive...
A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer [0.03%]
阿特朱单抗联合瓦利珠单抗(CDX-1127)与或不联合科美替尼治疗既往经治的不可切除胆道癌患者的II期随机研究
Thatcher Ross Heumann,Jiayun Lu,Hao Wang et al.
Thatcher Ross Heumann et al.
Purpose: The addition of MEK inhibition to PD-L1 blockade improves progression-free survival (PFS) in patients with advanced biliary tract cancer (BTC). While MEK inhibitors may increase tumor cell immunogenicity, they ca...
Camrelizumab, a patinib and radiotherapy in locally advanced, unresectable hepatocellular carcinoma: a phase 2 study [0.03%]
卡瑞利珠单抗、派安普利和放疗治疗局部晚期不可切除肝细胞癌的一项Ⅱ期研究
Hongzhi Wang,Kun Wang,Xuan Zheng et al.
Hongzhi Wang et al.
Purpose: Given the underexplored combination of immune checkpoint inhibitors, tyrosine kinase inhibitors (TKIs), and radiotherapy in locally advanced, unresectable hepatocellular carcinoma (HCC), this study aimed to evalu...
Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer [0.03%]
胆道癌靶向治疗的分子和临床决定因素
Darren Cowzer,Henry Walch,Pranita Atri et al.
Darren Cowzer et al.
Purpose: Actionable genomic alterations occur in all anatomic subsets of biliary tract cancer (BTC); however, targeted therapies have not shown a survival advantage over cytotoxics, and resistance mechanisms require furth...